Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.msard.2020.102592 http://scihub22266oqcxt.onion/10.1016/j.msard.2020.102592 33296987!7576324!33296987     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mult+Scler+Relat+Disord 2020 ; 46 (ä): 102592 Nephropedia Template TP {{tp|p=33296987|t=2020. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment |pdf=|usr=}}{{33296987}} gab.com Text Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment JO: Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=33296987 #FOAvip Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19. Twit Text FOAVip Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment ????Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=33296987 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33296987 #FOAvip English Wikipedia <ref>{{Cite pmid|33296987}}</ref> Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment #MMPMID33296987 Masuccio FG; Lo Re M; Bertolotto A; Capobianco M; Solaro C Mult Scler Relat Disord 2020[Nov]; 46 (ä): 102592 PMID33296987show ga Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Coronavirus Infections/*drug therapy/epidemiology/virology[MESH] |Female[MESH] |Humans[MESH] |Pneumonia, Viral/drug therapy[MESH] |SARS-CoV-2/drug effects/*pathogenicity[MESH]Benign SARS-CoV-2 infection in MOG-antibodies associated disorder duri(epmc).pdf DeepDyve Pubget Overpricing